nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—ABCB1—ovarian cancer	0.169	1	CbGaD
Lovastatin—SLCO1A2—Chlorambucil—ovarian cancer	0.119	0.217	CbGbCtD
Lovastatin—UGT2B7—Epirubicin—ovarian cancer	0.0655	0.119	CbGbCtD
Lovastatin—ABCC2—Paclitaxel—ovarian cancer	0.034	0.0617	CbGbCtD
Lovastatin—ABCC2—Carboplatin—ovarian cancer	0.032	0.0581	CbGbCtD
Lovastatin—ABCC2—Docetaxel—ovarian cancer	0.0246	0.0446	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0227	0.0412	CbGbCtD
Lovastatin—CYP3A7—Paclitaxel—ovarian cancer	0.0227	0.0412	CbGbCtD
Lovastatin—ABCB1—Topotecan—ovarian cancer	0.0224	0.0406	CbGbCtD
Lovastatin—ABCC2—Doxorubicin—ovarian cancer	0.0183	0.0333	CbGbCtD
Lovastatin—CYP3A5—Paclitaxel—ovarian cancer	0.017	0.0309	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0164	0.0298	CbGbCtD
Lovastatin—CYP3A7—Docetaxel—ovarian cancer	0.0164	0.0298	CbGbCtD
Lovastatin—CYP2C8—Paclitaxel—ovarian cancer	0.0164	0.0297	CbGbCtD
Lovastatin—ABCB1—Vinorelbine—ovarian cancer	0.0158	0.0286	CbGbCtD
Lovastatin—CYP2D6—Vinorelbine—ovarian cancer	0.0149	0.027	CbGbCtD
Lovastatin—CYP3A4—Topotecan—ovarian cancer	0.0134	0.0243	CbGbCtD
Lovastatin—CYP3A5—Docetaxel—ovarian cancer	0.0123	0.0223	CbGbCtD
Lovastatin—CYP2C9—Paclitaxel—ovarian cancer	0.0114	0.0207	CbGbCtD
Lovastatin—ABCB1—Paclitaxel—ovarian cancer	0.0111	0.0201	CbGbCtD
Lovastatin—CYP3A4—Vinorelbine—ovarian cancer	0.00944	0.0172	CbGbCtD
Lovastatin—ABCB1—Docetaxel—ovarian cancer	0.00801	0.0145	CbGbCtD
Lovastatin—CYP3A4—Paclitaxel—ovarian cancer	0.00664	0.0121	CbGbCtD
Lovastatin—ABCB1—Doxorubicin—ovarian cancer	0.00597	0.0108	CbGbCtD
Lovastatin—CYP2D6—Doxorubicin—ovarian cancer	0.00562	0.0102	CbGbCtD
Lovastatin—CYP3A4—Docetaxel—ovarian cancer	0.0048	0.00871	CbGbCtD
Lovastatin—HDAC2—oviduct—ovarian cancer	0.00474	0.062	CbGeAlD
Lovastatin—ITGAL—myometrium—ovarian cancer	0.00379	0.0496	CbGeAlD
Lovastatin—CYP3A4—Doxorubicin—ovarian cancer	0.00358	0.00649	CbGbCtD
Lovastatin—ITGAL—epithelium—ovarian cancer	0.00298	0.0389	CbGeAlD
Lovastatin—ITGAL—uterine cervix—ovarian cancer	0.00295	0.0386	CbGeAlD
Lovastatin—PON3—uterine cervix—ovarian cancer	0.00289	0.0379	CbGeAlD
Lovastatin—ITGAL—decidua—ovarian cancer	0.00281	0.0368	CbGeAlD
Lovastatin—ITGAL—endometrium—ovarian cancer	0.00267	0.0349	CbGeAlD
Lovastatin—ITGAL—bone marrow—ovarian cancer	0.00209	0.0273	CbGeAlD
Lovastatin—PON3—bone marrow—ovarian cancer	0.00205	0.0268	CbGeAlD
Lovastatin—ITGAL—female gonad—ovarian cancer	0.00201	0.0263	CbGeAlD
Lovastatin—ITGAL—vagina—ovarian cancer	0.002	0.0262	CbGeAlD
Lovastatin—PON3—female gonad—ovarian cancer	0.00197	0.0258	CbGeAlD
Lovastatin—PON3—vagina—ovarian cancer	0.00196	0.0257	CbGeAlD
Lovastatin—ITGAL—testis—ovarian cancer	0.00178	0.0233	CbGeAlD
Lovastatin—PON3—testis—ovarian cancer	0.00175	0.0229	CbGeAlD
Lovastatin—HDAC2—embryo—ovarian cancer	0.00146	0.0191	CbGeAlD
Lovastatin—HMGCR—myometrium—ovarian cancer	0.00137	0.0179	CbGeAlD
Lovastatin—ITGAL—lymph node—ovarian cancer	0.00129	0.0169	CbGeAlD
Lovastatin—HDAC2—epithelium—ovarian cancer	0.00119	0.0156	CbGeAlD
Lovastatin—HDAC2—uterine cervix—ovarian cancer	0.00118	0.0154	CbGeAlD
Lovastatin—HDAC2—decidua—ovarian cancer	0.00112	0.0147	CbGeAlD
Lovastatin—UGT2B7—female reproductive system—ovarian cancer	0.00108	0.0141	CbGeAlD
Lovastatin—HMGCR—epithelium—ovarian cancer	0.00107	0.014	CbGeAlD
Lovastatin—HDAC2—endometrium—ovarian cancer	0.00107	0.014	CbGeAlD
Lovastatin—HMGCR—uterine cervix—ovarian cancer	0.00106	0.0139	CbGeAlD
Lovastatin—HMGCR—decidua—ovarian cancer	0.00101	0.0133	CbGeAlD
Lovastatin—HDAC2—gonad—ovarian cancer	0.000989	0.0129	CbGeAlD
Lovastatin—HDAC2—uterus—ovarian cancer	0.000983	0.0129	CbGeAlD
Lovastatin—HMGCR—endometrium—ovarian cancer	0.000962	0.0126	CbGeAlD
Lovastatin—HMGCR—gonad—ovarian cancer	0.000893	0.0117	CbGeAlD
Lovastatin—HMGCR—uterus—ovarian cancer	0.000887	0.0116	CbGeAlD
Lovastatin—HDAC2—female reproductive system—ovarian cancer	0.000884	0.0116	CbGeAlD
Lovastatin—UGT2B7—testis—ovarian cancer	0.000871	0.0114	CbGeAlD
Lovastatin—HDAC2—bone marrow—ovarian cancer	0.000834	0.0109	CbGeAlD
Lovastatin—HDAC2—female gonad—ovarian cancer	0.000804	0.0105	CbGeAlD
Lovastatin—HDAC2—vagina—ovarian cancer	0.000799	0.0105	CbGeAlD
Lovastatin—HMGCR—female reproductive system—ovarian cancer	0.000797	0.0104	CbGeAlD
Lovastatin—SLCO1B1—female reproductive system—ovarian cancer	0.000764	0.01	CbGeAlD
Lovastatin—HMGCR—bone marrow—ovarian cancer	0.000753	0.00985	CbGeAlD
Lovastatin—HMGCR—female gonad—ovarian cancer	0.000725	0.00949	CbGeAlD
Lovastatin—HMGCR—vagina—ovarian cancer	0.000721	0.00944	CbGeAlD
Lovastatin—HDAC2—testis—ovarian cancer	0.000713	0.00933	CbGeAlD
Lovastatin—Simvastatin—ABCB1—ovarian cancer	0.000665	0.506	CrCbGaD
Lovastatin—Pravastatin—ABCB1—ovarian cancer	0.000651	0.495	CrCbGaD
Lovastatin—HMGCR—testis—ovarian cancer	0.000643	0.00842	CbGeAlD
Lovastatin—ABCC2—female reproductive system—ovarian cancer	0.000579	0.00758	CbGeAlD
Lovastatin—CYP2C8—endometrium—ovarian cancer	0.000524	0.00686	CbGeAlD
Lovastatin—CYP3A5—uterine cervix—ovarian cancer	0.000523	0.00685	CbGeAlD
Lovastatin—HDAC2—lymph node—ovarian cancer	0.000517	0.00676	CbGeAlD
Lovastatin—SLCO1A2—testis—ovarian cancer	0.000502	0.00657	CbGeAlD
Lovastatin—ABCC2—testis—ovarian cancer	0.000467	0.00612	CbGeAlD
Lovastatin—HMGCR—lymph node—ovarian cancer	0.000466	0.0061	CbGeAlD
Lovastatin—CYP2C19—vagina—ovarian cancer	0.00045	0.00589	CbGeAlD
Lovastatin—CYP2C8—female reproductive system—ovarian cancer	0.000434	0.00568	CbGeAlD
Lovastatin—CYP2C8—vagina—ovarian cancer	0.000393	0.00514	CbGeAlD
Lovastatin—CYP2C9—female reproductive system—ovarian cancer	0.000386	0.00505	CbGeAlD
Lovastatin—ABCB1—myometrium—ovarian cancer	0.000357	0.00467	CbGeAlD
Lovastatin—CYP3A5—female gonad—ovarian cancer	0.000357	0.00467	CbGeAlD
Lovastatin—CYP3A5—vagina—ovarian cancer	0.000354	0.00464	CbGeAlD
Lovastatin—CYP2C8—testis—ovarian cancer	0.00035	0.00459	CbGeAlD
Lovastatin—ABCB1—embryo—ovarian cancer	0.000343	0.0045	CbGeAlD
Lovastatin—ABCC2—lymph node—ovarian cancer	0.000339	0.00443	CbGeAlD
Lovastatin—CYP3A4—female reproductive system—ovarian cancer	0.000294	0.00385	CbGeAlD
Lovastatin—CYP2D6—female reproductive system—ovarian cancer	0.000289	0.00379	CbGeAlD
Lovastatin—ABCB1—epithelium—ovarian cancer	0.00028	0.00367	CbGeAlD
Lovastatin—ABCB1—uterine cervix—ovarian cancer	0.000278	0.00364	CbGeAlD
Lovastatin—ABCB1—decidua—ovarian cancer	0.000265	0.00347	CbGeAlD
Lovastatin—CYP2D6—female gonad—ovarian cancer	0.000263	0.00345	CbGeAlD
Lovastatin—ABCB1—endometrium—ovarian cancer	0.000251	0.00329	CbGeAlD
Lovastatin—Constipation—Vinorelbine—ovarian cancer	0.000236	0.00204	CcSEcCtD
Lovastatin—Pain—Vinorelbine—ovarian cancer	0.000236	0.00204	CcSEcCtD
Lovastatin—Chills—Paclitaxel—ovarian cancer	0.000234	0.00203	CcSEcCtD
Lovastatin—CYP2D6—testis—ovarian cancer	0.000234	0.00306	CbGeAlD
Lovastatin—ABCB1—gonad—ovarian cancer	0.000233	0.00305	CbGeAlD
Lovastatin—Hypersensitivity—Melphalan—ovarian cancer	0.000233	0.00202	CcSEcCtD
Lovastatin—ABCB1—uterus—ovarian cancer	0.000232	0.00303	CbGeAlD
Lovastatin—Asthenia—Topotecan—ovarian cancer	0.000231	0.00201	CcSEcCtD
Lovastatin—Alopecia—Paclitaxel—ovarian cancer	0.000231	0.002	CcSEcCtD
Lovastatin—Vomiting—Chlorambucil—ovarian cancer	0.00023	0.002	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Doxorubicin—ovarian cancer	0.00023	0.00199	CcSEcCtD
Lovastatin—Hepatic function abnormal—Doxorubicin—ovarian cancer	0.000228	0.00198	CcSEcCtD
Lovastatin—Pruritus—Topotecan—ovarian cancer	0.000228	0.00198	CcSEcCtD
Lovastatin—Photosensitivity—Doxorubicin—ovarian cancer	0.000227	0.00197	CcSEcCtD
Lovastatin—Feeling abnormal—Vinorelbine—ovarian cancer	0.000227	0.00197	CcSEcCtD
Lovastatin—Asthenia—Melphalan—ovarian cancer	0.000226	0.00196	CcSEcCtD
Lovastatin—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000226	0.00196	CcSEcCtD
Lovastatin—Flatulence—Paclitaxel—ovarian cancer	0.000224	0.00194	CcSEcCtD
Lovastatin—Purpura—Epirubicin—ovarian cancer	0.000224	0.00194	CcSEcCtD
Lovastatin—Pruritus—Melphalan—ovarian cancer	0.000223	0.00194	CcSEcCtD
Lovastatin—Vascular purpura—Doxorubicin—ovarian cancer	0.000223	0.00193	CcSEcCtD
Lovastatin—Dysgeusia—Paclitaxel—ovarian cancer	0.000223	0.00193	CcSEcCtD
Lovastatin—Hepatic failure—Doxorubicin—ovarian cancer	0.000222	0.00193	CcSEcCtD
Lovastatin—Hepatitis—Docetaxel—ovarian cancer	0.000221	0.00192	CcSEcCtD
Lovastatin—Diarrhoea—Topotecan—ovarian cancer	0.000221	0.00191	CcSEcCtD
Lovastatin—Back pain—Paclitaxel—ovarian cancer	0.00022	0.00191	CcSEcCtD
Lovastatin—Urticaria—Vinorelbine—ovarian cancer	0.000219	0.0019	CcSEcCtD
Lovastatin—Muscle spasms—Paclitaxel—ovarian cancer	0.000219	0.00189	CcSEcCtD
Lovastatin—Abdominal pain—Vinorelbine—ovarian cancer	0.000218	0.00189	CcSEcCtD
Lovastatin—Body temperature increased—Vinorelbine—ovarian cancer	0.000218	0.00189	CcSEcCtD
Lovastatin—Diarrhoea—Melphalan—ovarian cancer	0.000216	0.00187	CcSEcCtD
Lovastatin—Pain in extremity—Epirubicin—ovarian cancer	0.000216	0.00187	CcSEcCtD
Lovastatin—Nausea—Chlorambucil—ovarian cancer	0.000215	0.00186	CcSEcCtD
Lovastatin—Vision blurred—Paclitaxel—ovarian cancer	0.000214	0.00186	CcSEcCtD
Lovastatin—Dizziness—Topotecan—ovarian cancer	0.000213	0.00185	CcSEcCtD
Lovastatin—Tremor—Paclitaxel—ovarian cancer	0.000213	0.00185	CcSEcCtD
Lovastatin—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000211	0.00183	CcSEcCtD
Lovastatin—Erythema multiforme—Docetaxel—ovarian cancer	0.000209	0.00181	CcSEcCtD
Lovastatin—ABCB1—female reproductive system—ovarian cancer	0.000208	0.00273	CbGeAlD
Lovastatin—Angioedema—Paclitaxel—ovarian cancer	0.000208	0.0018	CcSEcCtD
Lovastatin—Purpura—Doxorubicin—ovarian cancer	0.000207	0.0018	CcSEcCtD
Lovastatin—Flushing—Docetaxel—ovarian cancer	0.000205	0.00178	CcSEcCtD
Lovastatin—Vomiting—Topotecan—ovarian cancer	0.000205	0.00178	CcSEcCtD
Lovastatin—Malaise—Paclitaxel—ovarian cancer	0.000205	0.00178	CcSEcCtD
Lovastatin—Vertigo—Paclitaxel—ovarian cancer	0.000204	0.00177	CcSEcCtD
Lovastatin—Leukopenia—Paclitaxel—ovarian cancer	0.000203	0.00176	CcSEcCtD
Lovastatin—Rash—Topotecan—ovarian cancer	0.000203	0.00176	CcSEcCtD
Lovastatin—Hypersensitivity—Vinorelbine—ovarian cancer	0.000203	0.00176	CcSEcCtD
Lovastatin—Dermatitis—Topotecan—ovarian cancer	0.000203	0.00176	CcSEcCtD
Lovastatin—Headache—Topotecan—ovarian cancer	0.000202	0.00175	CcSEcCtD
Lovastatin—Vomiting—Melphalan—ovarian cancer	0.000201	0.00174	CcSEcCtD
Lovastatin—Pain in extremity—Doxorubicin—ovarian cancer	0.0002	0.00173	CcSEcCtD
Lovastatin—Rash—Melphalan—ovarian cancer	0.000199	0.00173	CcSEcCtD
Lovastatin—Dermatitis—Melphalan—ovarian cancer	0.000199	0.00172	CcSEcCtD
Lovastatin—Chills—Docetaxel—ovarian cancer	0.000199	0.00172	CcSEcCtD
Lovastatin—Asthenia—Vinorelbine—ovarian cancer	0.000198	0.00172	CcSEcCtD
Lovastatin—ABCB1—bone marrow—ovarian cancer	0.000197	0.00257	CbGeAlD
Lovastatin—Alopecia—Docetaxel—ovarian cancer	0.000196	0.0017	CcSEcCtD
Lovastatin—Pruritus—Vinorelbine—ovarian cancer	0.000195	0.00169	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000194	0.00168	CcSEcCtD
Lovastatin—Chest pain—Paclitaxel—ovarian cancer	0.000194	0.00168	CcSEcCtD
Lovastatin—Arthralgia—Paclitaxel—ovarian cancer	0.000194	0.00168	CcSEcCtD
Lovastatin—Myalgia—Paclitaxel—ovarian cancer	0.000194	0.00168	CcSEcCtD
Lovastatin—Anxiety—Paclitaxel—ovarian cancer	0.000193	0.00167	CcSEcCtD
Lovastatin—Nausea—Topotecan—ovarian cancer	0.000192	0.00166	CcSEcCtD
Lovastatin—Discomfort—Paclitaxel—ovarian cancer	0.000191	0.00166	CcSEcCtD
Lovastatin—ABCB1—female gonad—ovarian cancer	0.000189	0.00248	CbGeAlD
Lovastatin—Dry mouth—Paclitaxel—ovarian cancer	0.000189	0.00164	CcSEcCtD
Lovastatin—Diarrhoea—Vinorelbine—ovarian cancer	0.000189	0.00164	CcSEcCtD
Lovastatin—Dysgeusia—Docetaxel—ovarian cancer	0.000189	0.00164	CcSEcCtD
Lovastatin—ABCB1—vagina—ovarian cancer	0.000188	0.00246	CbGeAlD
Lovastatin—Nausea—Melphalan—ovarian cancer	0.000188	0.00163	CcSEcCtD
Lovastatin—Confusional state—Paclitaxel—ovarian cancer	0.000187	0.00162	CcSEcCtD
Lovastatin—Influenza—Epirubicin—ovarian cancer	0.000186	0.00162	CcSEcCtD
Lovastatin—Back pain—Docetaxel—ovarian cancer	0.000186	0.00162	CcSEcCtD
Lovastatin—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000186	0.00161	CcSEcCtD
Lovastatin—Muscle spasms—Docetaxel—ovarian cancer	0.000185	0.00161	CcSEcCtD
Lovastatin—Eosinophilia—Epirubicin—ovarian cancer	0.000185	0.0016	CcSEcCtD
Lovastatin—Infection—Paclitaxel—ovarian cancer	0.000184	0.0016	CcSEcCtD
Lovastatin—Pancreatitis—Epirubicin—ovarian cancer	0.000183	0.00159	CcSEcCtD
Lovastatin—Dizziness—Vinorelbine—ovarian cancer	0.000182	0.00158	CcSEcCtD
Lovastatin—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000182	0.00157	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.00018	0.00156	CcSEcCtD
Lovastatin—Anorexia—Paclitaxel—ovarian cancer	0.000177	0.00153	CcSEcCtD
Lovastatin—Vomiting—Vinorelbine—ovarian cancer	0.000175	0.00152	CcSEcCtD
Lovastatin—Rash—Vinorelbine—ovarian cancer	0.000174	0.00151	CcSEcCtD
Lovastatin—Dermatitis—Vinorelbine—ovarian cancer	0.000174	0.00151	CcSEcCtD
Lovastatin—Headache—Vinorelbine—ovarian cancer	0.000173	0.0015	CcSEcCtD
Lovastatin—Influenza—Doxorubicin—ovarian cancer	0.000173	0.0015	CcSEcCtD
Lovastatin—Leukopenia—Docetaxel—ovarian cancer	0.000172	0.00149	CcSEcCtD
Lovastatin—Eosinophilia—Doxorubicin—ovarian cancer	0.000171	0.00148	CcSEcCtD
Lovastatin—Photosensitivity reaction—Epirubicin—ovarian cancer	0.00017	0.00148	CcSEcCtD
Lovastatin—Pancreatitis—Doxorubicin—ovarian cancer	0.000169	0.00147	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000169	0.00147	CcSEcCtD
Lovastatin—ABCB1—testis—ovarian cancer	0.000168	0.0022	CbGeAlD
Lovastatin—Insomnia—Paclitaxel—ovarian cancer	0.000168	0.00145	CcSEcCtD
Lovastatin—Paraesthesia—Paclitaxel—ovarian cancer	0.000167	0.00144	CcSEcCtD
Lovastatin—Dyspnoea—Paclitaxel—ovarian cancer	0.000165	0.00143	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000165	0.00143	CcSEcCtD
Lovastatin—Arthralgia—Docetaxel—ovarian cancer	0.000164	0.00142	CcSEcCtD
Lovastatin—Chest pain—Docetaxel—ovarian cancer	0.000164	0.00142	CcSEcCtD
Lovastatin—Myalgia—Docetaxel—ovarian cancer	0.000164	0.00142	CcSEcCtD
Lovastatin—Nausea—Vinorelbine—ovarian cancer	0.000164	0.00142	CcSEcCtD
Lovastatin—Dyspepsia—Paclitaxel—ovarian cancer	0.000163	0.00142	CcSEcCtD
Lovastatin—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000163	0.00141	CcSEcCtD
Lovastatin—Urinary tract infection—Epirubicin—ovarian cancer	0.000162	0.0014	CcSEcCtD
Lovastatin—Decreased appetite—Paclitaxel—ovarian cancer	0.000161	0.0014	CcSEcCtD
Lovastatin—Dry mouth—Docetaxel—ovarian cancer	0.00016	0.00139	CcSEcCtD
Lovastatin—Fatigue—Paclitaxel—ovarian cancer	0.00016	0.00139	CcSEcCtD
Lovastatin—Pain—Paclitaxel—ovarian cancer	0.000159	0.00138	CcSEcCtD
Lovastatin—Constipation—Paclitaxel—ovarian cancer	0.000159	0.00138	CcSEcCtD
Lovastatin—Confusional state—Docetaxel—ovarian cancer	0.000159	0.00137	CcSEcCtD
Lovastatin—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000158	0.00137	CcSEcCtD
Lovastatin—Anaphylactic shock—Docetaxel—ovarian cancer	0.000157	0.00136	CcSEcCtD
Lovastatin—Infection—Docetaxel—ovarian cancer	0.000156	0.00135	CcSEcCtD
Lovastatin—Sinusitis—Epirubicin—ovarian cancer	0.000156	0.00135	CcSEcCtD
Lovastatin—Thrombocytopenia—Docetaxel—ovarian cancer	0.000154	0.00133	CcSEcCtD
Lovastatin—Feeling abnormal—Paclitaxel—ovarian cancer	0.000153	0.00133	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000153	0.00132	CcSEcCtD
Lovastatin—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000152	0.00131	CcSEcCtD
Lovastatin—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000151	0.00131	CcSEcCtD
Lovastatin—Anorexia—Docetaxel—ovarian cancer	0.00015	0.0013	CcSEcCtD
Lovastatin—Urinary tract infection—Doxorubicin—ovarian cancer	0.00015	0.0013	CcSEcCtD
Lovastatin—Hepatitis—Epirubicin—ovarian cancer	0.000149	0.00129	CcSEcCtD
Lovastatin—Urticaria—Paclitaxel—ovarian cancer	0.000147	0.00128	CcSEcCtD
Lovastatin—Abdominal pain—Paclitaxel—ovarian cancer	0.000147	0.00127	CcSEcCtD
Lovastatin—Body temperature increased—Paclitaxel—ovarian cancer	0.000147	0.00127	CcSEcCtD
Lovastatin—Sinusitis—Doxorubicin—ovarian cancer	0.000144	0.00125	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000143	0.00124	CcSEcCtD
Lovastatin—Insomnia—Docetaxel—ovarian cancer	0.000142	0.00123	CcSEcCtD
Lovastatin—Paraesthesia—Docetaxel—ovarian cancer	0.000141	0.00122	CcSEcCtD
Lovastatin—Erythema multiforme—Epirubicin—ovarian cancer	0.000141	0.00122	CcSEcCtD
Lovastatin—Dyspnoea—Docetaxel—ovarian cancer	0.00014	0.00122	CcSEcCtD
Lovastatin—Flushing—Epirubicin—ovarian cancer	0.000139	0.0012	CcSEcCtD
Lovastatin—Dyspepsia—Docetaxel—ovarian cancer	0.000138	0.0012	CcSEcCtD
Lovastatin—Hepatitis—Doxorubicin—ovarian cancer	0.000138	0.0012	CcSEcCtD
Lovastatin—Decreased appetite—Docetaxel—ovarian cancer	0.000137	0.00118	CcSEcCtD
Lovastatin—Hypersensitivity—Paclitaxel—ovarian cancer	0.000137	0.00118	CcSEcCtD
Lovastatin—Fatigue—Docetaxel—ovarian cancer	0.000136	0.00118	CcSEcCtD
Lovastatin—Pain—Docetaxel—ovarian cancer	0.000134	0.00117	CcSEcCtD
Lovastatin—Constipation—Docetaxel—ovarian cancer	0.000134	0.00117	CcSEcCtD
Lovastatin—Chills—Epirubicin—ovarian cancer	0.000134	0.00116	CcSEcCtD
Lovastatin—Asthenia—Paclitaxel—ovarian cancer	0.000133	0.00115	CcSEcCtD
Lovastatin—Alopecia—Epirubicin—ovarian cancer	0.000132	0.00114	CcSEcCtD
Lovastatin—Pruritus—Paclitaxel—ovarian cancer	0.000131	0.00114	CcSEcCtD
Lovastatin—Erythema multiforme—Doxorubicin—ovarian cancer	0.000131	0.00113	CcSEcCtD
Lovastatin—Feeling abnormal—Docetaxel—ovarian cancer	0.00013	0.00112	CcSEcCtD
Lovastatin—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000129	0.00111	CcSEcCtD
Lovastatin—Flushing—Doxorubicin—ovarian cancer	0.000128	0.00111	CcSEcCtD
Lovastatin—Flatulence—Epirubicin—ovarian cancer	0.000128	0.00111	CcSEcCtD
Lovastatin—Dysgeusia—Epirubicin—ovarian cancer	0.000127	0.0011	CcSEcCtD
Lovastatin—Diarrhoea—Paclitaxel—ovarian cancer	0.000127	0.0011	CcSEcCtD
Lovastatin—Back pain—Epirubicin—ovarian cancer	0.000126	0.00109	CcSEcCtD
Lovastatin—Muscle spasms—Epirubicin—ovarian cancer	0.000125	0.00108	CcSEcCtD
Lovastatin—Abdominal pain—Docetaxel—ovarian cancer	0.000124	0.00108	CcSEcCtD
Lovastatin—Body temperature increased—Docetaxel—ovarian cancer	0.000124	0.00108	CcSEcCtD
Lovastatin—Chills—Doxorubicin—ovarian cancer	0.000124	0.00107	CcSEcCtD
Lovastatin—Dizziness—Paclitaxel—ovarian cancer	0.000123	0.00106	CcSEcCtD
Lovastatin—Vision blurred—Epirubicin—ovarian cancer	0.000122	0.00106	CcSEcCtD
Lovastatin—Alopecia—Doxorubicin—ovarian cancer	0.000122	0.00106	CcSEcCtD
Lovastatin—ABCB1—lymph node—ovarian cancer	0.000122	0.00159	CbGeAlD
Lovastatin—Ill-defined disorder—Epirubicin—ovarian cancer	0.000121	0.00105	CcSEcCtD
Lovastatin—Flatulence—Doxorubicin—ovarian cancer	0.000118	0.00103	CcSEcCtD
Lovastatin—Vomiting—Paclitaxel—ovarian cancer	0.000118	0.00102	CcSEcCtD
Lovastatin—Dysgeusia—Doxorubicin—ovarian cancer	0.000118	0.00102	CcSEcCtD
Lovastatin—Malaise—Epirubicin—ovarian cancer	0.000117	0.00102	CcSEcCtD
Lovastatin—Rash—Paclitaxel—ovarian cancer	0.000117	0.00101	CcSEcCtD
Lovastatin—Dermatitis—Paclitaxel—ovarian cancer	0.000117	0.00101	CcSEcCtD
Lovastatin—Vertigo—Epirubicin—ovarian cancer	0.000117	0.00101	CcSEcCtD
Lovastatin—Leukopenia—Epirubicin—ovarian cancer	0.000116	0.00101	CcSEcCtD
Lovastatin—Back pain—Doxorubicin—ovarian cancer	0.000116	0.00101	CcSEcCtD
Lovastatin—Headache—Paclitaxel—ovarian cancer	0.000116	0.00101	CcSEcCtD
Lovastatin—Hypersensitivity—Docetaxel—ovarian cancer	0.000116	0.001	CcSEcCtD
Lovastatin—Muscle spasms—Doxorubicin—ovarian cancer	0.000116	0.001	CcSEcCtD
Lovastatin—Vision blurred—Doxorubicin—ovarian cancer	0.000113	0.000982	CcSEcCtD
Lovastatin—Asthenia—Docetaxel—ovarian cancer	0.000113	0.000978	CcSEcCtD
Lovastatin—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000112	0.000967	CcSEcCtD
Lovastatin—Pruritus—Docetaxel—ovarian cancer	0.000111	0.000964	CcSEcCtD
Lovastatin—Arthralgia—Epirubicin—ovarian cancer	0.000111	0.000959	CcSEcCtD
Lovastatin—Chest pain—Epirubicin—ovarian cancer	0.000111	0.000959	CcSEcCtD
Lovastatin—Myalgia—Epirubicin—ovarian cancer	0.000111	0.000959	CcSEcCtD
Lovastatin—Anxiety—Epirubicin—ovarian cancer	0.00011	0.000956	CcSEcCtD
Lovastatin—Nausea—Paclitaxel—ovarian cancer	0.00011	0.000955	CcSEcCtD
Lovastatin—Discomfort—Epirubicin—ovarian cancer	0.000109	0.000948	CcSEcCtD
Lovastatin—Malaise—Doxorubicin—ovarian cancer	0.000108	0.00094	CcSEcCtD
Lovastatin—Dry mouth—Epirubicin—ovarian cancer	0.000108	0.000938	CcSEcCtD
Lovastatin—Vertigo—Doxorubicin—ovarian cancer	0.000108	0.000936	CcSEcCtD
Lovastatin—Leukopenia—Doxorubicin—ovarian cancer	0.000108	0.000933	CcSEcCtD
Lovastatin—Diarrhoea—Docetaxel—ovarian cancer	0.000108	0.000933	CcSEcCtD
Lovastatin—Confusional state—Epirubicin—ovarian cancer	0.000107	0.000927	CcSEcCtD
Lovastatin—Anaphylactic shock—Epirubicin—ovarian cancer	0.000106	0.000919	CcSEcCtD
Lovastatin—Infection—Epirubicin—ovarian cancer	0.000105	0.000913	CcSEcCtD
Lovastatin—Dizziness—Docetaxel—ovarian cancer	0.000104	0.000901	CcSEcCtD
Lovastatin—Thrombocytopenia—Epirubicin—ovarian cancer	0.000104	0.0009	CcSEcCtD
Lovastatin—Arthralgia—Doxorubicin—ovarian cancer	0.000102	0.000887	CcSEcCtD
Lovastatin—Myalgia—Doxorubicin—ovarian cancer	0.000102	0.000887	CcSEcCtD
Lovastatin—Chest pain—Doxorubicin—ovarian cancer	0.000102	0.000887	CcSEcCtD
Lovastatin—Anxiety—Doxorubicin—ovarian cancer	0.000102	0.000884	CcSEcCtD
Lovastatin—Discomfort—Doxorubicin—ovarian cancer	0.000101	0.000877	CcSEcCtD
Lovastatin—Anorexia—Epirubicin—ovarian cancer	0.000101	0.000876	CcSEcCtD
Lovastatin—Dry mouth—Doxorubicin—ovarian cancer	0.0001	0.000868	CcSEcCtD
Lovastatin—Vomiting—Docetaxel—ovarian cancer	0.0001	0.000867	CcSEcCtD
Lovastatin—Rash—Docetaxel—ovarian cancer	9.91e-05	0.000859	CcSEcCtD
Lovastatin—Dermatitis—Docetaxel—ovarian cancer	9.9e-05	0.000859	CcSEcCtD
Lovastatin—Confusional state—Doxorubicin—ovarian cancer	9.89e-05	0.000858	CcSEcCtD
Lovastatin—Headache—Docetaxel—ovarian cancer	9.85e-05	0.000854	CcSEcCtD
Lovastatin—Anaphylactic shock—Doxorubicin—ovarian cancer	9.81e-05	0.000851	CcSEcCtD
Lovastatin—Infection—Doxorubicin—ovarian cancer	9.75e-05	0.000845	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	9.66e-05	0.000838	CcSEcCtD
Lovastatin—Thrombocytopenia—Doxorubicin—ovarian cancer	9.61e-05	0.000833	CcSEcCtD
Lovastatin—Insomnia—Epirubicin—ovarian cancer	9.59e-05	0.000832	CcSEcCtD
Lovastatin—Paraesthesia—Epirubicin—ovarian cancer	9.52e-05	0.000826	CcSEcCtD
Lovastatin—Dyspnoea—Epirubicin—ovarian cancer	9.46e-05	0.00082	CcSEcCtD
Lovastatin—Anorexia—Doxorubicin—ovarian cancer	9.35e-05	0.000811	CcSEcCtD
Lovastatin—Nausea—Docetaxel—ovarian cancer	9.34e-05	0.00081	CcSEcCtD
Lovastatin—Dyspepsia—Epirubicin—ovarian cancer	9.34e-05	0.000809	CcSEcCtD
Lovastatin—Decreased appetite—Epirubicin—ovarian cancer	9.22e-05	0.000799	CcSEcCtD
Lovastatin—Fatigue—Epirubicin—ovarian cancer	9.14e-05	0.000793	CcSEcCtD
Lovastatin—Pain—Epirubicin—ovarian cancer	9.07e-05	0.000786	CcSEcCtD
Lovastatin—Constipation—Epirubicin—ovarian cancer	9.07e-05	0.000786	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	8.94e-05	0.000775	CcSEcCtD
Lovastatin—Insomnia—Doxorubicin—ovarian cancer	8.88e-05	0.000769	CcSEcCtD
Lovastatin—Paraesthesia—Doxorubicin—ovarian cancer	8.81e-05	0.000764	CcSEcCtD
Lovastatin—Dyspnoea—Doxorubicin—ovarian cancer	8.75e-05	0.000758	CcSEcCtD
Lovastatin—Feeling abnormal—Epirubicin—ovarian cancer	8.74e-05	0.000758	CcSEcCtD
Lovastatin—Gastrointestinal pain—Epirubicin—ovarian cancer	8.67e-05	0.000752	CcSEcCtD
Lovastatin—Dyspepsia—Doxorubicin—ovarian cancer	8.64e-05	0.000749	CcSEcCtD
Lovastatin—Decreased appetite—Doxorubicin—ovarian cancer	8.53e-05	0.000739	CcSEcCtD
Lovastatin—Fatigue—Doxorubicin—ovarian cancer	8.46e-05	0.000733	CcSEcCtD
Lovastatin—Urticaria—Epirubicin—ovarian cancer	8.43e-05	0.00073	CcSEcCtD
Lovastatin—Pain—Doxorubicin—ovarian cancer	8.39e-05	0.000727	CcSEcCtD
Lovastatin—Constipation—Doxorubicin—ovarian cancer	8.39e-05	0.000727	CcSEcCtD
Lovastatin—Body temperature increased—Epirubicin—ovarian cancer	8.38e-05	0.000727	CcSEcCtD
Lovastatin—Abdominal pain—Epirubicin—ovarian cancer	8.38e-05	0.000727	CcSEcCtD
Lovastatin—Feeling abnormal—Doxorubicin—ovarian cancer	8.09e-05	0.000701	CcSEcCtD
Lovastatin—Gastrointestinal pain—Doxorubicin—ovarian cancer	8.02e-05	0.000696	CcSEcCtD
Lovastatin—Hypersensitivity—Epirubicin—ovarian cancer	7.81e-05	0.000677	CcSEcCtD
Lovastatin—Urticaria—Doxorubicin—ovarian cancer	7.8e-05	0.000676	CcSEcCtD
Lovastatin—Abdominal pain—Doxorubicin—ovarian cancer	7.76e-05	0.000672	CcSEcCtD
Lovastatin—Body temperature increased—Doxorubicin—ovarian cancer	7.76e-05	0.000672	CcSEcCtD
Lovastatin—Asthenia—Epirubicin—ovarian cancer	7.61e-05	0.00066	CcSEcCtD
Lovastatin—Pruritus—Epirubicin—ovarian cancer	7.5e-05	0.00065	CcSEcCtD
Lovastatin—Diarrhoea—Epirubicin—ovarian cancer	7.26e-05	0.000629	CcSEcCtD
Lovastatin—Hypersensitivity—Doxorubicin—ovarian cancer	7.23e-05	0.000627	CcSEcCtD
Lovastatin—Asthenia—Doxorubicin—ovarian cancer	7.04e-05	0.00061	CcSEcCtD
Lovastatin—Dizziness—Epirubicin—ovarian cancer	7.01e-05	0.000608	CcSEcCtD
Lovastatin—Pruritus—Doxorubicin—ovarian cancer	6.94e-05	0.000602	CcSEcCtD
Lovastatin—Vomiting—Epirubicin—ovarian cancer	6.74e-05	0.000585	CcSEcCtD
Lovastatin—Diarrhoea—Doxorubicin—ovarian cancer	6.71e-05	0.000582	CcSEcCtD
Lovastatin—Rash—Epirubicin—ovarian cancer	6.69e-05	0.00058	CcSEcCtD
Lovastatin—Dermatitis—Epirubicin—ovarian cancer	6.68e-05	0.000579	CcSEcCtD
Lovastatin—Headache—Epirubicin—ovarian cancer	6.64e-05	0.000576	CcSEcCtD
Lovastatin—Dizziness—Doxorubicin—ovarian cancer	6.49e-05	0.000563	CcSEcCtD
Lovastatin—Nausea—Epirubicin—ovarian cancer	6.3e-05	0.000546	CcSEcCtD
Lovastatin—Vomiting—Doxorubicin—ovarian cancer	6.24e-05	0.000541	CcSEcCtD
Lovastatin—Rash—Doxorubicin—ovarian cancer	6.19e-05	0.000536	CcSEcCtD
Lovastatin—Dermatitis—Doxorubicin—ovarian cancer	6.18e-05	0.000536	CcSEcCtD
Lovastatin—Headache—Doxorubicin—ovarian cancer	6.15e-05	0.000533	CcSEcCtD
Lovastatin—Nausea—Doxorubicin—ovarian cancer	5.83e-05	0.000505	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism—ABCB1—ovarian cancer	1.39e-05	0.00016	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—SLC2A1—ovarian cancer	1.38e-05	0.000159	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	1.38e-05	0.000159	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PPP1CC—ovarian cancer	1.37e-05	0.000157	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—BRIP1—ovarian cancer	1.37e-05	0.000157	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—TYMS—ovarian cancer	1.37e-05	0.000157	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.36e-05	0.000156	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.36e-05	0.000156	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PIK3CG—ovarian cancer	1.36e-05	0.000156	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CYP1B1—ovarian cancer	1.33e-05	0.000152	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TERT—ovarian cancer	1.32e-05	0.000152	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.31e-05	0.00015	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—ABCB1—ovarian cancer	1.3e-05	0.000149	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—YAP1—ovarian cancer	1.29e-05	0.000148	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PPP2R1A—ovarian cancer	1.28e-05	0.000147	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—TYMS—ovarian cancer	1.28e-05	0.000147	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.28e-05	0.000147	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PIK3CB—ovarian cancer	1.27e-05	0.000146	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.27e-05	0.000146	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—CAV1—ovarian cancer	1.27e-05	0.000145	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—AKT1—ovarian cancer	1.25e-05	0.000144	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.24e-05	0.000143	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.24e-05	0.000143	CbGpPWpGaD
Lovastatin—HDAC2—Disease—ERBB2—ovarian cancer	1.23e-05	0.000142	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CAV1—ovarian cancer	1.22e-05	0.00014	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MTOR—ovarian cancer	1.22e-05	0.00014	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PIK3CB—ovarian cancer	1.22e-05	0.00014	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.22e-05	0.00014	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PIK3CD—ovarian cancer	1.19e-05	0.000137	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—ABCB1—ovarian cancer	1.19e-05	0.000137	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	1.18e-05	0.000135	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—ESR1—ovarian cancer	1.18e-05	0.000135	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.18e-05	0.000135	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—TYMS—ovarian cancer	1.17e-05	0.000134	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL6ST—ovarian cancer	1.16e-05	0.000133	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PIK3CG—ovarian cancer	1.15e-05	0.000132	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CDKN1B—ovarian cancer	1.14e-05	0.000131	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—YAP1—ovarian cancer	1.12e-05	0.000129	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PIK3CG—ovarian cancer	1.11e-05	0.000128	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—APC—ovarian cancer	1.11e-05	0.000128	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.11e-05	0.000127	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—CAV1—ovarian cancer	1.1e-05	0.000127	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTEN—ovarian cancer	1.1e-05	0.000126	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—ABCB1—ovarian cancer	1.09e-05	0.000126	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.09e-05	0.000125	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.08e-05	0.000124	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CTNNB1—ovarian cancer	1.08e-05	0.000124	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—TYMS—ovarian cancer	1.07e-05	0.000123	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—FASN—ovarian cancer	1.05e-05	0.000121	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.05e-05	0.000121	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTEN—ovarian cancer	1.05e-05	0.000121	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.04e-05	0.00012	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PIK3CB—ovarian cancer	1.04e-05	0.000119	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—SLC5A5—ovarian cancer	1.04e-05	0.000119	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CAV1—ovarian cancer	1.03e-05	0.000118	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CYTB—ovarian cancer	1.02e-05	0.000118	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PIK3CD—ovarian cancer	1.01e-05	0.000116	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PIK3CG—ovarian cancer	1e-05	0.000115	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—SLC2A1—ovarian cancer	1e-05	0.000115	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—YAP1—ovarian cancer	9.99e-06	0.000115	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.9e-06	0.000114	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.89e-06	0.000114	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PIK3CD—ovarian cancer	9.78e-06	0.000112	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—YAP1—ovarian cancer	9.75e-06	0.000112	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.74e-06	0.000112	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—MAPK3—ovarian cancer	9.68e-06	0.000111	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CYP1B1—ovarian cancer	9.6e-06	0.00011	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—CAV1—ovarian cancer	9.43e-06	0.000108	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—MYC—ovarian cancer	9.41e-06	0.000108	CbGpPWpGaD
Lovastatin—HDAC2—Disease—STAT3—ovarian cancer	9.4e-06	0.000108	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NRAS—ovarian cancer	9.38e-06	0.000108	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PIK3CG—ovarian cancer	9.37e-06	0.000108	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—YAP1—ovarian cancer	9.19e-06	0.000106	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—FASN—ovarian cancer	9.13e-06	0.000105	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—YAP1—ovarian cancer	9.11e-06	0.000105	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.02e-06	0.000104	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.01e-06	0.000103	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MAPK3—ovarian cancer	8.98e-06	0.000103	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTEN—ovarian cancer	8.98e-06	0.000103	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—SLC5A5—ovarian cancer	8.98e-06	0.000103	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PPP1CC—ovarian cancer	8.96e-06	0.000103	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—BRIP1—ovarian cancer	8.96e-06	0.000103	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PIK3CB—ovarian cancer	8.83e-06	0.000101	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PIK3CD—ovarian cancer	8.83e-06	0.000101	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	8.82e-06	0.000101	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MYC—ovarian cancer	8.74e-06	0.0001	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.69e-06	9.98e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—SLC2A1—ovarian cancer	8.67e-06	9.95e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CAV1—ovarian cancer	8.65e-06	9.93e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—ERBB2—ovarian cancer	8.63e-06	9.91e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	8.59e-06	9.86e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MAPK1—ovarian cancer	8.55e-06	9.82e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—EGFR—ovarian cancer	8.55e-06	9.81e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MTOR—ovarian cancer	8.52e-06	9.78e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PIK3CB—ovarian cancer	8.52e-06	9.78e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	8.51e-06	9.77e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.49e-06	9.75e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CYP1B1—ovarian cancer	8.31e-06	9.54e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PIK3CD—ovarian cancer	8.24e-06	9.46e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CXCL8—ovarian cancer	8.19e-06	9.4e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—FASN—ovarian cancer	8.14e-06	9.35e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KRAS—ovarian cancer	8.07e-06	9.27e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—SLC5A5—ovarian cancer	8.01e-06	9.2e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CDKN1B—ovarian cancer	8e-06	9.18e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—FASN—ovarian cancer	7.95e-06	9.13e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.93e-06	9.1e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—ABCB1—ovarian cancer	7.9e-06	9.07e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PIK3CG—ovarian cancer	7.88e-06	9.05e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CASP3—ovarian cancer	7.84e-06	9e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL2—ovarian cancer	7.82e-06	8.99e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—SLC5A5—ovarian cancer	7.82e-06	8.98e-05	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PIK3CA—ovarian cancer	7.77e-06	8.92e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—TYMS—ovarian cancer	7.76e-06	8.91e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—SLC2A1—ovarian cancer	7.74e-06	8.89e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PIK3CB—ovarian cancer	7.69e-06	8.83e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTEN—ovarian cancer	7.63e-06	8.77e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CCND1—ovarian cancer	7.63e-06	8.76e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.58e-06	8.7e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CTNNB1—ovarian cancer	7.55e-06	8.67e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—SLC2A1—ovarian cancer	7.55e-06	8.67e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	7.55e-06	8.67e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—FASN—ovarian cancer	7.49e-06	8.6e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—FASN—ovarian cancer	7.43e-06	8.53e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CYP1B1—ovarian cancer	7.42e-06	8.52e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PIK3CA—ovarian cancer	7.42e-06	8.52e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MMP9—ovarian cancer	7.41e-06	8.5e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	7.37e-06	8.46e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—SLC5A5—ovarian cancer	7.37e-06	8.46e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PTEN—ovarian cancer	7.36e-06	8.45e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.34e-06	8.42e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—SLC5A5—ovarian cancer	7.31e-06	8.39e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CYP1B1—ovarian cancer	7.24e-06	8.31e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PIK3CB—ovarian cancer	7.18e-06	8.24e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—SLC2A1—ovarian cancer	7.12e-06	8.17e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—SLC2A1—ovarian cancer	7.06e-06	8.1e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PIK3CD—ovarian cancer	6.93e-06	7.95e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.91e-06	7.93e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HRAS—ovarian cancer	6.86e-06	7.88e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—ABCB1—ovarian cancer	6.84e-06	7.86e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CYP1B1—ovarian cancer	6.82e-06	7.83e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CYP1B1—ovarian cancer	6.76e-06	7.77e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—TYMS—ovarian cancer	6.72e-06	7.72e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—VEGFA—ovarian cancer	6.65e-06	7.64e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTEN—ovarian cancer	6.65e-06	7.63e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—STAT3—ovarian cancer	6.58e-06	7.56e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	6.58e-06	7.55e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	6.58e-06	7.55e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NRAS—ovarian cancer	6.57e-06	7.54e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—IL6—ovarian cancer	6.57e-06	7.54e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.55e-06	7.52e-05	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—AKT1—ovarian cancer	6.53e-06	7.49e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PPP2R1A—ovarian cancer	6.42e-06	7.37e-05	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—AKT1—ovarian cancer	6.35e-06	7.29e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PIK3CA—ovarian cancer	6.33e-06	7.27e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MAPK3—ovarian cancer	6.29e-06	7.22e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CAV1—ovarian cancer	6.25e-06	7.18e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTEN—ovarian cancer	6.2e-06	7.12e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MYC—ovarian cancer	6.12e-06	7.03e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—ABCB1—ovarian cancer	6.11e-06	7.01e-05	CbGpPWpGaD
Lovastatin—HDAC2—Disease—AKT1—ovarian cancer	6.06e-06	6.96e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	6.05e-06	6.95e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PIK3CB—ovarian cancer	6.04e-06	6.93e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—YAP1—ovarian cancer	6.01e-06	6.9e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—TYMS—ovarian cancer	6e-06	6.89e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	6e-06	6.89e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MAPK1—ovarian cancer	5.99e-06	6.87e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—EGFR—ovarian cancer	5.98e-06	6.87e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.97e-06	6.86e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—TYMS—ovarian cancer	5.86e-06	6.72e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PIK3CG—ovarian cancer	5.7e-06	6.54e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTEN—ovarian cancer	5.68e-06	6.53e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KRAS—ovarian cancer	5.65e-06	6.49e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—ABCB1—ovarian cancer	5.62e-06	6.45e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—ABCB1—ovarian cancer	5.57e-06	6.4e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—TYMS—ovarian cancer	5.52e-06	6.34e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—TYMS—ovarian cancer	5.47e-06	6.28e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CAV1—ovarian cancer	5.42e-06	6.22e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PIK3CA—ovarian cancer	5.39e-06	6.18e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTEN—ovarian cancer	5.22e-06	5.99e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PIK3CA—ovarian cancer	5.19e-06	5.96e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.17e-06	5.94e-05	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—AKT1—ovarian cancer	5.17e-06	5.94e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—ovarian cancer	5.02e-06	5.77e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PIK3CD—ovarian cancer	5.01e-06	5.75e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PIK3CG—ovarian cancer	4.93e-06	5.67e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—FASN—ovarian cancer	4.9e-06	5.62e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CAV1—ovarian cancer	4.83e-06	5.55e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.82e-06	5.53e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—HRAS—ovarian cancer	4.81e-06	5.52e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CAV1—ovarian cancer	4.72e-06	5.42e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PIK3CA—ovarian cancer	4.69e-06	5.39e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.65e-06	5.34e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.62e-06	5.3e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL6—ovarian cancer	4.6e-06	5.28e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.46e-06	5.12e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CAV1—ovarian cancer	4.45e-06	5.11e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CAV1—ovarian cancer	4.41e-06	5.06e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PIK3CG—ovarian cancer	4.4e-06	5.06e-05	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—AKT1—ovarian cancer	4.4e-06	5.05e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PIK3CA—ovarian cancer	4.38e-06	5.03e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PIK3CB—ovarian cancer	4.36e-06	5.01e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PIK3CD—ovarian cancer	4.34e-06	4.98e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PIK3CG—ovarian cancer	4.3e-06	4.94e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—AKT1—ovarian cancer	4.24e-06	4.87e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.21e-06	4.84e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PIK3CG—ovarian cancer	4.05e-06	4.65e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PIK3CG—ovarian cancer	4.02e-06	4.61e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	4.01e-06	4.61e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.96e-06	4.54e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PIK3CD—ovarian cancer	3.87e-06	4.45e-05	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—AKT1—ovarian cancer	3.83e-06	4.4e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PIK3CB—ovarian cancer	3.78e-06	4.34e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.78e-06	4.34e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTEN—ovarian cancer	3.77e-06	4.33e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.68e-06	4.23e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.67e-06	4.22e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—TYMS—ovarian cancer	3.61e-06	4.14e-05	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—AKT1—ovarian cancer	3.58e-06	4.11e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3.56e-06	4.09e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PIK3CD—ovarian cancer	3.53e-06	4.05e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PIK3CB—ovarian cancer	3.37e-06	3.87e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PIK3CB—ovarian cancer	3.29e-06	3.78e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—AKT1—ovarian cancer	3.28e-06	3.76e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTEN—ovarian cancer	3.27e-06	3.75e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PIK3CB—ovarian cancer	3.1e-06	3.56e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.08e-06	3.53e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—AKT1—ovarian cancer	3.01e-06	3.45e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTEN—ovarian cancer	2.92e-06	3.35e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CAV1—ovarian cancer	2.91e-06	3.34e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTEN—ovarian cancer	2.85e-06	3.27e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTEN—ovarian cancer	2.68e-06	3.08e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.66e-06	3.06e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTEN—ovarian cancer	2.66e-06	3.05e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.65e-06	3.04e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.33e-06	2.67e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PIK3CA—ovarian cancer	2.3e-06	2.65e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—AKT1—ovarian cancer	2.17e-06	2.5e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PIK3CA—ovarian cancer	2.06e-06	2.36e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.03e-06	2.33e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.01e-06	2.31e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.89e-06	2.17e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—AKT1—ovarian cancer	1.88e-06	2.16e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.88e-06	2.15e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTEN—ovarian cancer	1.75e-06	2.01e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—AKT1—ovarian cancer	1.68e-06	1.93e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—AKT1—ovarian cancer	1.64e-06	1.88e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—AKT1—ovarian cancer	1.55e-06	1.77e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—AKT1—ovarian cancer	1.53e-06	1.76e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.24e-06	1.42e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—AKT1—ovarian cancer	1.01e-06	1.16e-05	CbGpPWpGaD
